

COMPLETE LISTING OF CLAIMS

1. (CURRENTLY AMENDED) A method of assessing a predisposition in an individual to presenting preeclampsia during pregnancy ~~a physiological disorder associated with magnesium-binding defect in an individual~~, comprising: measuring the level of peptide in a sample of body fluid of said individual, wherein said peptide is selected from the group consisting of: ~~comprising one or more of~~ amino acid sequence set forth in SEQ ID NO:1, ~~or~~ amino acid sequence set forth in SEQ ID NO:2, and ~~or~~ amino acid sequence set forth in SEQ ID NO:4, and comparing said level of peptide to a standard, wherein the standard represents the average level of said peptide in normal body fluid, and whereby a significantly lower level of said peptide in the sample is indicative of a predisposition of said individual to preeclampsia.

2. (CANCELED)

3. (CURRENTLY AMENDED) The method of claim 1 ~~2~~ wherein the level of said peptide in said sample is measured by an immunological assay that can indicate the presence of one or more of amino acid sequence set forth in SEQ ID NO:1, or amino acid sequence set forth in SEQ ID NO:2, or amino acid sequence set forth in SEQ ID NO:4.

4. (ORIGINAL) The method of claim 3 wherein said immunological assay utilizes a monoclonal antibody.

5. (ORIGINAL) The method of claim 4 wherein said monoclonal antibody cross reacts with each of said peptides.

6. (ORIGINAL) The method of claim 3 wherein said immunological assay is an enzyme-linked immunosorbent assay, and said sample of body fluid is blood.

7. (CANCELED)

8. (CANCELED)
9. (CANCELED)
10. (CANCELED)
11. (CANCELED)
12. (CANCELED)
13. (CANCELED)
14. (CANCELED)
15. (CANCELED)
16. (CANCELED)
17. (CANCELED)
18. (CANCELED)
19. (CURRENTLY AMENDED) A method for monitoring progress in treatment of preeclampsia ~~a physiological disorder associated with magnesium binding defect~~ in an individual, comprising:
 - a. measuring the level of peptide in a sample of body fluid of said individual, wherein said peptide ~~is comprising one or more of~~ selected from the group consisting of: amino acid sequence set forth in SEQ ID NO:1, ~~or~~ amino acid sequence set forth in SEQ ID NO:2, and ~~or~~ amino acid sequence set forth in SEQ ID NO:4;
 - b. treating preeclampsia in the individual,
 - c. repeating step a, and
 - d. ~~b.~~ comparing said level of peptide of step a. to the level of said peptide of step c, ~~after treatment,~~

whereby a significant increase in the level of said peptide after treatment is indicative of the progress of treatment of said individual.

20. (CANCELED)

21. (CANCELED)

22. (CANCELED)

23. (CANCELED)

24. (CANCELED)

25. (CANCELED)

26. (CANCELED)

27. (CANCELED)

28. (CANCELED)

29. (CANCELED)

30. (CANCELED)